We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.
Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
UMass Chan Affiliations
Department of Emergency MedicineDocument Type
Journal ArticlePublication Date
2018-05-19Keywords
antibiotic resistanceCAP
community-acquired pneumonia
emergency department
macrolide resistance
Bacterial Infections and Mycoses
Emergency Medicine
Metadata
Show full item recordAbstract
BACKGROUND: Emergency physicians are under pressure to prescribe an antibiotic early in the treatment course of a patient with community-acquired pneumonia (CAP). Macrolides are recommended first-line empirical therapy for the outpatient treatment of CAP in patients without associated comorbidities; however, resistance rates to macrolides in the United States are on the rise. OBJECTIVE: This review considers macrolide use for CAP in the emergency department by reviewing the microbiologic environment in the United States and whether macrolides can overcome in vitro resistance during actual clinical use. Alternatives to macrolides for CAP are briefly discussed. DISCUSSION: Resistance to macrolides is now above 25% in all regions of the United States, and resistance to other antibiotics is also on the rise. The failure of outpatient macrolide treatment for CAP because of resistance rates increases the burden of the disease both in terms of the patient and health economics. No definitive answer is available on whether macrolides will achieve treatment success despite infection with in vitro resistant strains. When selecting a therapy, a balance needs to be struck between spectrum of activity targeted against the probable etiology (including atypical pathogens) for respiratory tract infections and the need for first-time success. CONCLUSIONS: Currently available macrolides are now facing resistance rates that cloud their recommendation as a first-line treatment for CAP. Clinicians need a better understanding of their own local resistance rates, while hospitals need to do a better job in describing low- and high-level resistance rates to better inform their physicians.Source
J Emerg Med. 2018 May 19. pii: S0736-4679(18)30370-6. doi: 10.1016/j.jemermed.2018.04.031. Link to article on publisher's site
DOI
10.1016/j.jemermed.2018.04.031Permanent Link to this Item
http://hdl.handle.net/20.500.14038/28466PubMed ID
29789175Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.jemermed.2018.04.031